Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Harbin Pharmaceutical Group Sanjing Pharmaceutical Nojie is a specialized pharmaceutical subsidiary of the Harbin Pharmaceutical Group (Hayao), one of China's largest state-owned pharmaceutical conglomerates. The company focuses on the production and commercialization of over-the-counter (OTC) medicines, traditional Chinese medicine (TCM) preparations, and pediatric healthcare products. It is particularly well-known for its liquid oral formulations, including widely used pediatric cough and asthma syrups and nutritional supplements. Operating within the Sanjing Pharmaceutical brand ecosystem, the company leverages advanced manufacturing facilities in Harbin to supply the domestic Chinese market. Its business model is centered on high-volume production of essential medicines and consumer health products that address common family ailments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Harbin Pharmaceutical Group Sanjing Pharmaceutical Nojie.